arGEN-X BV is broadening its therapeutic antibody collaboration with Shire plc Initiated in March 2012, the existing alliance is focused on arGEN-X using its SIMPLE Antibody(TM) discovery platform to create novel human antibody therapeutics addressing diverse rare and unmet diseases being pursued by Shire. Building upon the success of the partnership to date, the companies have now instigated an additional discovery program, addressing a new and exciting therapeutic opportunity. arGEN-X continues to be responsible for all antibody discovery and certain preclinical activities, while Shire will conduct all disease-relevant preclinical work, as well as clinical and commercial development of therapeutic antibody products.

arGEN-X receives research funding and success-based payments, as well as milestones and royalties on products developed under the collaboration.